Obizur (susoctocog alfa) / Takeda, Ipsen - LARVOL DELTA

Profiling Cell-Free DNA Methylation Patterns in Metastatic NSCLC Treated With Immune Checkpoint Inhibition Therapy. (IASLC-WCLC 2026) - "Differential methylation analysis identified several significantly differentially methylated regions distinguishing responders from non-responders, including hypermethylation in non-responders at the promotor region of OBI1 and CRAT37 (adj...Our findings suggest that cfMeDIP-seq-derived methylation signatures may distinguish responders from non-responders and capture biologically relevant mechanisms of resistance. Ongoing work integrating these data within a multi-omics framework aims to improve prediction of response to checkpoint inhibition and inform personalised treatment strategies."

cfDNA • Checkpoint inhibition • Epigenetic controller • IO biomarker • Metastases • Tumor mutational burden • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1 • TMB

TAK-672-4002: A Study of OBIZUR in Adults With Acquired Hemophilia A (AHA) in South Korea (clinicaltrials.gov) - P=N/A | N=9 | Recruiting | Sponsor: Takeda | Trial completion date: Sep 2026 ➔ Dec 2026 | Trial primary completion date: Sep 2026 ➔ Dec 2026

Trial completion date • Trial primary completion date • Hematological Disorders • Hemophilia • Hemophilia A • Rare Diseases

Severe Spontaneous Hematoma in an Elderly Female: A Case of Acquired Hemophilia A. (PubMed, J Community Hosp Intern Med Perspect) - "Management included recombinant activated factor VII (rFVIIa), porcine FVIII (Obizur), corticosteroids, and rituximab, leading to clinical stabilization. We also review diagnostic criteria, the role of inhibitor levels in monitoring, and current treatment guidelines, including the emerging role of emicizumab."

Journal • Hematological Disorders • Hemophilia • Hemophilia A • Immunology • Rare Diseases

A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia A (clinicaltrials.gov) - P=N/A | N=25 | Recruiting | Sponsor: Takeda | Trial completion date: Oct 2029 ➔ May 2028 | Trial primary completion date: Oct 2029 ➔ May 2028

Trial completion date • Trial primary completion date • Hematological Disorders • Hemophilia • Hemophilia A • Rare Diseases

Sequential Use of Recombinant Porcine Factor VIII and Early Emicizumab in Acquired Hemophilia A: A Case Series. (PubMed, EJHaem) - "Recombinant porcine factor VIII (rpFVIII, susoctocog alfa) controls acute bleeding, while emicizumab provides prophylaxis. Larger studies are needed. The authors have confirmed clinical trial registration is not needed for this submission."

Journal • Preclinical • Cardiovascular • Hematological Disorders • Hemophilia • Hemophilia A • Immunology • Rare Diseases • Thrombosis

SUCCESSFUL HEMODIALYSIS INITIATION IN ACQUIRED HEMOPHILIA A MANAGED WITH SUSOCTOCOG ALFA AND EMICIZUMAB (ISN-WCN 2026) - "Hemostatic therapy was prioritized to safely continue HD.Results Initial hemostasis with recombinant activated factor VII (rFVIIa; eptacog alfa) was insufficient. To our knowledge, this is the first report documenting HD initiation and maintenance in AHA using the sequential susoctocog alfa followed by emicizumab. This case highlights an infection-conscious practical strategy for frail patients-prioritizing rapid procedural hemostasis with rpFVIII when rFVIIa response is inadequate, followed by emicizumab prophylaxis to sustain bleed prevention and minimize steroid or IST exposure."

Glomerulonephritis • Hematological Disorders • Hemophilia • Hemophilia A • Infectious Disease • Nephrology • Pneumonia • Pulmonary Disease • Rare Diseases • Renal Disease • Respiratory Diseases

Long-read Sequencing Reveals Repeat Expansions and Large Structural Variants in Oral Squamous Cell Carcinoma. (PubMed, Genomics Proteomics Bioinformatics) - "Notably, one SRE located within the promoter region of the OBI1 gene is present in 45% of OSCC samples...Furthermore, we found that the frequently amplified region 11q13 in HNSCC is prone to large-scale somatic SVs, affecting the expression of ANO1, FADD, and CTTN, thereby confirming the association of SVs in this region with OSCC development. Our study provides novel insights into the role of somatic SVs in OSCC, especially with respect to SREs and large-scale SVs in critical genomic regions, thereby enhancing our comprehension of the molecular pathogenesis of OSCC."

Journal • Head and Neck Cancer • Oncology • Oral Cancer • Solid Tumor • Squamous Cell Carcinoma • ANO1 • CTTN • FADD

Successful hemodialysis initiation in acquired hemophilia a managed with susoctocog alfa and emicizumab. (PubMed, CEN Case Rep) - "Recombinant activated factor VII (rFVIIa, eptacog alfa) failed to control the bleeding; however, recombinant porcine sequence factor VIII (rpFVIII, susoctocog alfa) proved effective, enabling the safe placement of a long-term indwelling catheter for hemodialysis. To the best of our knowledge, there have been no prior reports of AHA cases requiring hemodialysis that were successfully treated with susoctocog alfa and emicizumab. This case highlights the potential role of these agents in optimizing hemostatic strategies for AHA patients undergoing hemodialysis."

Journal • Acute Kidney Injury • Glomerulonephritis • Hematological Disorders • Hemophilia • Hemophilia A • Immunology • Infectious Disease • Nephrology • Pneumonia • Rare Diseases • Renal Disease • Respiratory Diseases

Targeting early immunologic decline in acquired hemophilia A: A case for prophylactic rituximab (ASH 2025) - "We present the case of an 81-year-old man with idiopathic AHA and a mechanical aortic valve on chronic coumadin...Following treatment with triple immunosuppressive therapy including prednisone, rituximab, and cyclophosphamide, he achieved remission...Beyond its clinical impact, this approach may also offer significant cost savings by reducing the need for costly agents such as recombinant FVIII (obizur) or emicizumab. Further investigation is warranted to define relapse thresholds, evaluate safety, and determine the broader applicability of prophylactic immunosuppression in AHA patients."

Clinical • Cardiovascular • Hematological Disorders • Hemophilia • Hemophilia A • Immunology • Rare Diseases • Thrombocytopenic Purpura

Unexplained bleeding and a hidden inhibitor: A case of late-onset acquired hemophilia A (ASH 2025) - "The patient was treated initially with recombinant porcine Factor VIII (Obizur) without sustained response, then switched to recombinant activated Factor VII (NovoSeven) for hemostasis. Immunosuppressive therapy with prednisone and rituximab was initiated... AHA should be considered in elderly patients with unexplained bleeding and isolated prolonged aPTT, even following trauma. Increased awareness and timely intervention can significantly improve outcomes in this rare but potentially fatal disorder."

Clinical • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Diabetes • Diabetic Nephropathy • Hemophilia • Hemophilia A • Hypertension • Immunology • Ischemic stroke • Metabolic Disorders • Nephrology • Rare Diseases • Renal Disease • Type 2 Diabetes Mellitus

Susoctocog alfa for major surgery in acquired Hemophilia A (ASH 2025) - "As rescue therapy, rpFVIII was also effective in most life-threatening situations. Thesefindings may inform future guidelines and best practices for managing surgical emergencies in patientswith AHA."

Surgery • Cardiovascular • Gynecology • Hematological Disorders • Hemophilia • Hemophilia A • Rare Diseases

Distinct Co-methylation Patterns in African and European Populations and Their Genetic Associations. (PubMed, Genomics Proteomics Bioinformatics) - "Between individuals of European and African ancestry, 101 CMRs exhibited population-specific DNAm patterns (Pop-CMRs), including 91 Pop-CMRs not found in previous investigations, which spanned genes (e.g., CCDC42, GYPE, MAP3K20, and OBI1) related to diseases (e.g., malaria infection and diabetes) with different prevalence and incidence rates between populations...Additionally, subsets of Pop-CMRs could be applicable in East Asian populations and peripheral blood-based tissues. This study provides insights into DNAm differences across the genome between populations and explores their associations with genetic variants and biological relevance, advancing our understanding of epigenetic roles in population specificity."

Journal • Diabetes • Infectious Disease • Malaria • Metabolic Disorders • CDC42

Concomitant Acquired Hemophilia A and Acquired Von Willebrand Syndrome from Distinctive Autoantibodies: Case Report. (PubMed, Hematol Rep) - "The patient was started on immunosuppression with prednisone, cyclophosphamide, and intravenous immunoglobulin, alongside recombinant porcine FVIII replacement, susoctocog alfa. The patient had two further relapses; the most recent was treated with Rituximab, following which remission has been maintained. Given the potential therapeutic implications, VWF testing should be considered as part of the diagnostic workup for AHA."

Journal • Gastroenterology • Hematological Disorders • Hemophilia • Hemophilia A • Rare Diseases

Pharmacokinetic strategies for achieving precise factor VIII control with susoctocog alfa in acquired hemophilia A. (PubMed, J Thromb Haemost) - "PK estimates from limited sampling effectively guided rpFVIII bolus and continuous infusion dosing. Continuous infusion provided steady FVIII levels and may offer a practical alternative to bolus dosing."

Journal • PK/PD data • Hematological Disorders • Hemophilia • Hemophilia A • Rare Diseases

TAK-672-4002: A Study of OBIZUR in Adults With Acquired Hemophilia A (AHA) in South Korea (clinicaltrials.gov) - P=N/A | N=9 | Recruiting | Sponsor: Takeda | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Disorders • Hemophilia • Hemophilia A • Rare Diseases

Acquired Hemophilia A: insights from a 6-year experience in Liguria Italy (ISTH 2025) - "Among available treatments, susoctocog α, when administered at a loading dose of 100 U/kg, demonstrated high efficacy in controlling bleeding...Most diagnoses (21 out of 22) were made in central and western Liguria, highlighting a significant geographic disparity (Table 1 and Figure 1). Table or Figure Upload"

Cardiovascular • Hematological Disorders • Hemophilia • Hemophilia A • Rare Diseases • Thrombosis

TAK-672-4002: A Study of OBIZUR in Adults With Acquired Hemophilia A (AHA) in South Korea (clinicaltrials.gov) - P=N/A | N=9 | Not yet recruiting | Sponsor: Takeda | Initiation date: Sep 2024 ➔ Dec 2024

Trial initiation date • Hematological Disorders • Hemophilia • Hemophilia A • Rare Diseases

Genetic Foundations of Nellore Traits: A Gene Prioritization and Functional Analyses of Genome-Wide Association Study Results. (PubMed, Genes (Basel)) - "The prioritized candidate genes were GFRA4, RFWD3, SERTAD2, KIZ, REM2, and ANKRD34B for reproduction; RFWD3, TMEM120A, MIEF2, FOXRED2, DUSP29, CARHSP1, OBI1, JOSD1, NOP58, and LOXL1-AS1 for the carcass; ANKRD34B and JOSD1 for growth traits; and no genes were prioritized for morphological traits. The functional analysis pinpointed the following genes: KIZ (plays a crucial role in spindle organization, which is essential in forming a robust mitotic centrosome), DUSP29 (involved in muscle cell differentiation), and JOSD1 (involved in protein deubiquitination, thereby improving growth). The enrichment of the functional candidate genes identified in this study highlights that these genes play an important role in the expression of reproduction, carcass, and growth traits in Nellore cattle."

Journal • Targeted Protein Degradation • NOP58 • RFWD3

Cross-reacting antiporcine factor VIII inhibitors in patients with acquired hemophilia A. (PubMed, Res Pract Thromb Haemost) - "•Recombinant porcine factor VIII (rpFVIII) is a hemostatic treatment for bleeding in acquired hemophilia A.•The efficacy of rpFVIII can be negatively affected by cross-reacting anti-human FVIII antibodies.•In this cohort, 52% of patients with acquired hemophilia A had baseline cross-reacting antibodies.•Cross-reacting antibodies were associated with decreased FVIII activity levels post-rpFVIII infusion."

Journal • Hematological Disorders • Hemophilia • Hemophilia A • Rare Diseases

Acquired haemophilia: Update in 2024 (PubMed, Rev Med Interne) - "Eradication of inhibitor should be established as soon as the diagnosis is confirmed with steroid alone often associated with cytotoxic agents or rituximab, depending on FVIII activity and inhibitor titer. The purpose of this review is to summarize the epidemiology, etiopathogenesis, diagnosis, treatment of AHA and discuss current recommendations."

Journal • Review • Hematological Disorders • Hemophilia • Immunology • Oncology • Rare Diseases

Real-world use of recombinant porcine sequence factor VIII in the treatment of acquired hemophilia A: EU PASS. (PubMed, Ther Adv Hematol) - P=N/A, P2/3 | "Recombinant porcine factor VIII (rpFVIII; susoctocog alfa) is indicated for the treatment of bleeding events (BEs) in adults with acquired hemophilia A (AHA)...Results from this real-world study support the use of rpFVIII for AHA, aligning with findings from the clinical trial of rpFVIII (NCT01178294) in the treatment of BEs in adults with AHA. EUPAS16055; NCT03199794."

Journal • Preclinical • Real-world • Real-world evidence • Cardiovascular • Hematological Disorders • Hemophilia • Immunology • Rare Diseases

Efficacy and safety of recombinant porcine factor VIII in Japanese patients with acquired hemophilia A. (PubMed, Int J Hematol) - P2/3 | "This phase II/III open-label study evaluated the safety and efficacy of recombinant porcine factor VIII (rpFVIII, susoctocog alfa) in adults with AHA and severe bleeding episodes in Japan (NCT04580407)...This study supports the use of rpFVIII as a novel therapy in the clinical management of patients with AHA in Japan. rpFVIII was approved for treating bleeding episodes in adults with AHA in Japan in 2024."

Journal • Preclinical • Cardiovascular • Hematological Disorders • Hemophilia • Rare Diseases

A Study of OBIZUR in Adults With Acquired Hemophilia A (AHA) in South Korea (clinicaltrials.gov) - P=N/A | N=9 | Not yet recruiting | Sponsor: Takeda

New trial • Hematological Disorders • Hemophilia • Rare Diseases

A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia A (clinicaltrials.gov) - P=N/A | N=25 | Recruiting | Sponsor: Takeda

New trial • Hematological Disorders • Hemophilia • Rare Diseases

Identification of FVIII inhibitors by anti-FVIII ELISA assay and Bethesda assays in tandem to identify anti-Factor VIII inhibitors (ISTH 2024) - "Bovine-based reagents are used to assess for inhibitors in the presence of emicizumab. Porcine-based Bethesda assay measures FVIII inhibition with porcine FVIII therapy (e.g. obizur)... 218 anti-FVIII results were reviewed. 91% of patients showed correlation between ELISA and Bethesda assays whereas 9% did not. 5/218 (2%) patients had positive Nijmegen Bethesda with negative ELISA."

Hematological Disorders • Hemophilia • Rare Diseases